Verve Therapeutics (VERV) Expected to Announce Earnings on Wednesday

Verve Therapeutics (NASDAQ:VERV) is expected to be issuing its Q1 2025 quarterly earnings data before the market opens on Wednesday, May 14th. Analysts expect the company to announce earnings of ($0.71) per share for the quarter.

Verve Therapeutics (NASDAQ:VERV) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.58) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.14. Verve Therapeutics had a negative return on equity of 35.23% and a negative net margin of 807.65%. The company had revenue of $13.08 million during the quarter, compared to the consensus estimate of $3.94 million. On average, analysts expect Verve Therapeutics to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Verve Therapeutics Trading Down 5.6%

VERV stock opened at $4.23 on Monday. The company’s 50 day moving average is $4.99 and its two-hundred day moving average is $5.92. Verve Therapeutics has a twelve month low of $2.86 and a twelve month high of $9.31. The stock has a market cap of $377.07 million, a P/E ratio of -1.72 and a beta of 1.82.

Analysts Set New Price Targets

VERV has been the topic of several recent research reports. William Blair reissued an “outperform” rating on shares of Verve Therapeutics in a research note on Friday, February 21st. Canaccord Genuity Group increased their price objective on shares of Verve Therapeutics from $32.00 to $39.00 and gave the company a “buy” rating in a research note on Tuesday, April 15th. Royal Bank of Canada decreased their price objective on Verve Therapeutics from $17.00 to $15.00 and set an “outperform” rating on the stock in a report on Tuesday, March 4th. Cantor Fitzgerald raised shares of Verve Therapeutics from a “neutral” rating to an “overweight” rating in a research report on Tuesday, April 15th. Finally, HC Wainwright lifted their price target on shares of Verve Therapeutics from $15.00 to $25.00 and gave the company a “buy” rating in a research report on Monday, April 14th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Verve Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $25.75.

About Verve Therapeutics

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.